Study S000037

NIDA CTN-0152: Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder: A Pragmatic, Multi-site, Double-blind, Randomized, Placebo-controlled Trial (TAB)

ClinicalTrials.gov record

Registration

Registration: NCT06651177
Acronym: TAB
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 310
Start: 2026-01-29
Primary completion: 2027-09-30
Lead sponsor: T. John Winhusen, PhD
Conditions: Opioid Use Disorder; Opioid Use Disorder, Moderate; Opioid Use Disorder, Severe
Interventions: DRUG:Tirzepatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: NIH:UG1DA013732

Registered primary outcomes

6-month retention in BUP treatment [6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.